These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17968934)

  • 1. Macrophage activation is a key component in the pathogenesis of systemic juvenile idiopathic arthritis: comment on the article by Blessing et al.
    Bloom BJ
    Arthritis Rheum; 2007 Nov; 56(11):3877-8. PubMed ID: 17968934
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome.
    Maeno N; Takei S; Imanaka H; Yamamoto K; Kuriwaki K; Kawano Y; Oda H
    Arthritis Rheum; 2004 Jun; 50(6):1935-8. PubMed ID: 15188370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition and management of macrophage activation syndrome in juvenile arthritis.
    Kelly A; Ramanan AV
    Curr Opin Rheumatol; 2007 Sep; 19(5):477-81. PubMed ID: 17762614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does red-man reaction stimulate macrophage activation syndrome in children with systemic juvenile idiopathic arthritis?
    Olgar S; Ertugrul T; Devecioglu O; Nisli K; Omeroglu RE
    J Rheumatol; 2007 Dec; 34(12):2491-4. PubMed ID: 18061966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case report of macrophage activation syndrome complicated by systemic onset juvenile idiopathic arthritis].
    Zhao Y; Cao LF
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Dec; 9(6):610. PubMed ID: 18082055
    [No Abstract]   [Full Text] [Related]  

  • 6. Thymic function and immune senescence in juvenile idiopathic arthritis: comment on the article by Prelog et al.
    Lorenzi AR; Foster HE; Isaacs JD
    Arthritis Rheum; 2009 Jan; 60(1):310-1; author reply 311-2. PubMed ID: 19116926
    [No Abstract]   [Full Text] [Related]  

  • 7. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Eraso R; Gedalia A; Espinoza LR
    J Rheumatol; 2002 May; 29(5):1104; author reply 1104-5. PubMed ID: 12022333
    [No Abstract]   [Full Text] [Related]  

  • 8. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?
    Ramanan AV; Grom AA
    Rheumatology (Oxford); 2005 Nov; 44(11):1350-3. PubMed ID: 15956091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.
    Behrens EM; Beukelman T; Paessler M; Cron RQ
    J Rheumatol; 2007 May; 34(5):1133-8. PubMed ID: 17343315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome.
    Fall N; Barnes M; Thornton S; Luyrink L; Olson J; Ilowite NT; Gottlieb BS; Griffin T; Sherry DD; Thompson S; Glass DN; Colbert RA; Grom AA
    Arthritis Rheum; 2007 Nov; 56(11):3793-804. PubMed ID: 17968951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mass in adolescents with early-onset juvenile idiopathic arthritis: comment on the article by Lien et al.
    Roth J
    Arthritis Rheum; 2004 Jun; 50(6):2036. PubMed ID: 15188384
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?
    de Benedetti F; Martini A
    Arthritis Rheum; 2005 Mar; 52(3):687-93. PubMed ID: 15751082
    [No Abstract]   [Full Text] [Related]  

  • 13. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al.
    Maeno N; Takei S; Nomura Y; Imanaka H; Hokonohara M; Miyata K
    Arthritis Rheum; 2002 Sep; 46(9):2539-41; author reply 2541-2. PubMed ID: 12355506
    [No Abstract]   [Full Text] [Related]  

  • 14. What is juvenile psoriatic arthritis? Comment on the article by Stoll et al.
    Martini A
    Arthritis Rheum; 2007 Apr; 56(4):1368. PubMed ID: 17393443
    [No Abstract]   [Full Text] [Related]  

  • 15. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell?
    Behrens EM
    Autoimmun Rev; 2008 Feb; 7(4):305-8. PubMed ID: 18295734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood.
    Avcin T; Tse SM; Schneider R; Ngan B; Silverman ED
    J Pediatr; 2006 May; 148(5):683-6. PubMed ID: 16737887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).
    Behrens EM; Beukelman T; Gallo L; Spangler J; Rosenkranz M; Arkachaisri T; Ayala R; Groh B; Finkel TH; Cron RQ
    J Rheumatol; 2008 Feb; 35(2):343-8. PubMed ID: 18085728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis.
    Hazen MM; Woodward AL; Hofmann I; Degar BA; Grom A; Filipovich AH; Binstadt BA
    Arthritis Rheum; 2008 Feb; 58(2):567-70. PubMed ID: 18240215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation syndrome--what's in a name!
    Ramanan AV; Schneider R
    J Rheumatol; 2003 Dec; 30(12):2513-6. PubMed ID: 14719185
    [No Abstract]   [Full Text] [Related]  

  • 20. A model for the potential contribution of HLA-DR-restricted macrophage activation to the pathogenesis of rheumatoid arthritis: comment on the article by Cantwell et al.
    Dialynas DP; Yu J
    Arthritis Rheum; 1998 Aug; 41(8):1515-6. PubMed ID: 9704656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.